FDA Orphan Status for an Oral Retinitis Pigmentosa Candidate: What It Means

Retinitis pigmentosa (RP) slowly steals night vision and peripheral field, and rhodopsin-related autosomal dominant RP (RHO-adRP) still has no approved therapy. The FDA has granted orphan drug designation to OCT-980, an investigational oral small molecule from Octant designed to help misfolded rhodopsin traffic correctly inside photoreceptors.

What orphan designation does—and does not—do

Orphan status supports development of drugs for rare diseases with incentives such as potential tax credits and fee exemptions, and eligibility for seven years of U.S. market exclusivity if approved. It does not prove the drug works, does not shorten FDA review by itself, and does not make the medicine available outside trials.

Where the clinical program stands

• Phase 1a single-ascending-dose work in healthy volunteers in Australia is complete.
• An open-label phase 1b/2 multiple-ascending-dose study is enrolling adults 18–65 with genetically confirmed RHO-adRP at U.S. sites for up to 48 weeks of oral dosing.
• Eligibility requires relatively preserved acuity (above 70 ETDRS letters) and excludes prior ocular surgery or ocular gene therapy.
• Primary end points focus on safety and tolerability; functional measures such as acuity and microperimetry are secondary. Primary completion is estimated around November 2028.
• No patient efficacy or safety results have been publicly reported yet.

Neutral referral stance

Khanna Vision Institute does not manage inherited retinal disease specialty care. When night blindness, progressive field loss, or a known RP diagnosis arises, we refer to a retina or inherited-retinal-disease specialist and encourage genetic counseling. Byron L. Lam, MD, of Bascom Palmer, has noted that an oral corrector could complement gene-based approaches if long-term safety and benefit are shown.

• Ask whether genetic testing has identified a RHO variant and its functional class.
• Protect remaining vision with UV care, vitamin discussions guided by a specialist, and low-vision resources when needed.
• Be wary of unverified “RP cures” online while legitimate trials continue.

How to read trial news responsibly

Orphan designation, first-patient-dosed announcements, and conference abstracts are milestones, not finish lines. Ask specialists which outcome measures would convince them a therapy is meaningful for your genetic subtype, and how trial eligibility relates to your current acuity and prior procedures.

General eye-comfort reading while you navigate specialty care: epilasikmd.com.

Source: FDA designates OCT-980 as orphan drug for retinitis pigmentosa (Optometry Times, 10/28/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.